The Oncotype DX® Breast Recurrence Score™

From the moment she is diagnosed, your patient counts on you to recommend the best treatment plan for her. You can count on the Oncotype DX Breast Recurrence Score.

Only the Breast Recurrence Score
is validated for both prediction
of adjuvant therapy benefit and
prognosis.
The Breast Recurrence Score is a comprehensive 21-gene assay that provides a clearer picture of individual tumor biology, allowing you to make treatment decisions with increased confidence and insight.

Through its prediction of adjuvant therapy benefit as well as the likelihood of 10-year distant recurrence, the Breast Recurrence Score offers critical information not available from any other genomic test or traditional measure.

Studies show that use of the Breast Recurrence Score result changes treatment decisions approximately 30% of the time1 and addresses the clinical challenge of guiding therapy for those patients who will benefit from treatment while sparing other patients the rigors of unnecessary chemotherapy.

Only the Breast Recurrence Score

Breast Cancer

Breast Cancer 

 

 

 

REFERENCES

1. Burke et al. EBCC 2014.
2. Paik et al. N Engl J Med. 2004.
3. Paik et al. J Clin Oncol. 2006.
4. Dowsett et al. J Clin Oncol. 2010.
5. Albain et al. Lancet Oncol. 2010.
6. Habel et al. Breast Cancer Res. 2006.
7. Toi et al. Cancer. 2010.
8. NCCN Breast cancer guidelines. V1. 2015.
9. Harris et al. J Clin Oncol. 2007.
10. NICE Diagnostics Guidance 10. 2013.
11. Senkus et al. Ann Oncol. 2013.
12. Goldhirsch et al. Ann Oncol. 2013.
Next: Clinical Challenge